Browsing Tag
NMIBC
8 posts
What the latest UTOPIA trial data reveal about UGN-103’s competitive position in LG-IR-NMIBC
UroGen Pharma Ltd.’s UGN-103 posted strong Phase 3 bladder cancer durability data. Discover what it means for NMIBC competition and growth.
Verana Health and Guardant Health link genomics and real-world data to accelerate precision oncology drug
Verana Health and Guardant Health (GH) combine EHR and genomic data to accelerate oncology drug development. Read the full strategic analysis.
ImmunityBio (NASDAQ: IBRX) secures Saudi FDA approval for ANKTIVA in BCG-unresponsive bladder cancer
ImmunityBio secures Saudi approval for ANKTIVA in NMIBC. Find out how this reshapes the company’s MENA strategy and immunotherapy ambitions.
Relmada gains FDA support for dual Phase 3 study paths of NDV-01 in non-muscle invasive bladder cancer
Find out how Relmada secured FDA alignment on dual Phase 3 paths for NDV-01 in NMIBC, opening two routes toward approval and a potential new bladder-sparing therapy.
Ferring bags Adstiladrin FDA approval in non-muscle invasive bladder cancer
Swiss biopharmaceutical company Ferring Pharmaceuticals has received approval for its Adstiladrin (nadofaragene firadenovec-vncg) gene therapy from the US…
Aura Biosciences begins dosing in belzupacap sarotalocan phase 1 trial in NMIBC
Aura Biosciences said that it has dosed the first patient in a phase 1 clinical trial of its…
Aura Biosciences gets FDA fast track status for belzupacap sarotalocan
Aura Biosciences has secured fast track designation for belzupacap sarotalocan (AU-011) from the US Food and Drug Administration…
LIPAC Oncology takes NMIBC treatment TBC-1002 into phase 2 A trial
Investigational NMIBC treatment TBC-1002 : LIPAC Oncology said that it has wrapped up a phase 1 clinical trial…